December 26, 2017 / 1:11 PM / 10 months ago

BUZZ-Aptose: FDA grants 'orphan' status to blood cancer drug

** Canadian drug developer’s U.S.-listed stock up 42.7 pct at $2.54 premarket - set to open at highest in more than a year

** FDA grants orphan status to CG’806, Aptose’s treatment for acute myeloid leukemia

** Orphan status is given to treatments addressing diseases that affect less than 200,000 people, with benefits like seven-year market exclusivity and tax credits

** Up to Friday’s close, APTO up 28.6 pct this year vs 21.3 pct gain in the Nasdaq biotech index (Reporting by Medha Singh in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below